{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36.8","upperLimit":"50.3","value":"43.7"},{"groupId":"OG001","lowerLimit":"29.5","upperLimit":"42.6","value":"36.0"},{"groupId":"OG002","lowerLimit":"23.1","upperLimit":"35.7","value":"29.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"209"},{"groupId":"OG002","value":"207"}],"units":"Participants"}],"description":"Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"MEDI4736 (Durvalumab) + Tremelimumab","id":"OG000","title":"Combination Therapy"},{"description":"MEDI4736 (Durvalumab)","id":"OG001","title":"Monotherapy"},{"description":"Standard of Care Chemotherapy Treatment","id":"OG002","title":"Standard of Care"}],"paramType":"NUMBER","populationDescription":"The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:\n\n≥25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ≥25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control","reportingStatus":"POSTED","timeFrame":"From randomization date until death due to any cause, assessed up to 24 months or the data cut-off date (27JAN2020).","title":"Alive at 24 Months (OS24), PD-L1-High Analysis Set","type":"SECONDARY","unitOfMeasure":"percentage of participants"}